Related Experiment Videos
Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa
1Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Summary
Engineered factor VIII (FVIII) protein IR8 shows enhanced stability and activity for hemophilia A treatment. This genetically modified FVIII resists inactivation, offering a promising therapeutic advancement.
Area of Science:
- Biochemistry
- Molecular Biology
- Hematology
Background:
- Hemophilia A patients require frequent factor VIII (FVIII) infusions.
- FVIII activity is limited by its instability after thrombin activation.
- FVIII is susceptible to subunit dissociation and proteolytic inactivation.
Purpose of the Study:
- To engineer and characterize a novel FVIII protein, IR8, with enhanced in vitro stability.
- To improve FVIII resistance to subunit dissociation and proteolytic inactivation.
Main Methods:
- Genetic engineering of FVIII by deleting residues 794-1689 to covalently attach the A2 domain to the light chain.
- Introduction of missense mutations at thrombin and activated protein C inactivation sites.
- Production and characterization of IR8 in transfected COS-1 monkey cells.
Main Results:
- IR8 exhibited a single-chain structure with maximal activity after cleavage at Arg-372.
- IR8 showed 5-fold higher specific activity than wild-type (WT) FVIII.
- IR8 retained 38% activity after 4 hours, while WT FVIII was inactivated within 10 minutes.
- IR8 demonstrated altered binding to von Willebrand factor (vWF) but retained activity in the presence of ESH8 antibody.
Conclusions:
- The engineered IR8 protein possesses significantly enhanced in vitro stability and activity.
- Resistance to A2 subunit dissociation contributes to IR8's stability and abrogates ESH8 antibody inhibition.
- Rationale design through genetic engineering can improve protein therapeutics like FVIII.